- £1.66bn
- £720.67m
- $548.51m
RCS - Hutchmed China Ltd - NMPA approval for ELUNATE with TYVYT
AnnouncementREG - Hutchmed China Ltd - Announcement on Results of Annual General Meeting
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Announces NDA Acceptance in China
AnnouncementREG - Hutchmed China Ltd - 2025 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at AACR Annual Meeting 2026
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Phase III Trial of HMPL-760
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Update on Licensed Oncology Product in China
AnnouncementREG - Hutchmed China Ltd - Directorate change
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2025 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Global Trial of ATTC Candidate
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Final Results
AnnouncementRCS - Hutchmed China Ltd - Publication of Phase III Results in The Lancet
AnnouncementRCS - Hutchmed China Ltd - Positive Topline Results of Phase III Trial
AnnouncementRCS - Hutchmed China Ltd - Surufatinib + Camrelizumab PDAC Phase 3 initiation
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
Announcement